{
    "root": "54623e7c-32c6-407a-b619-a52c14df0fa2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "AMONDYS 45",
    "value": "20240112",
    "ingredients": [
        {
            "name": "casimersen",
            "code": "X8UHF7SX0R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14984"
        },
        {
            "name": "sodium chloride",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "potassium chloride",
            "code": "660YQ98I10",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32588"
        },
        {
            "name": "potassium phosphate, monobasic",
            "code": "4J9FJ0HL51",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26020"
        },
        {
            "name": "sodium phosphate, dibasic, anhydrous",
            "code": "22ADO53M6F",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "sodium hydroxide",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "hydrochloric acid",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "water",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "amondys 45 indicated treatment duchenne muscular dystrophy ( dmd ) patients confirmed mutation dmd gene amenable exon 45 skipping . indication approved accelerated approval based increase dystrophin production skeletal muscle observed patients treated amondys 45 [ ( 14 ) ] . continued approval indication may contingent upon verification benefit confirmatory trials .",
        "doid_entities": [
            {
                "text": "duchenne muscular dystrophy (DOID:11723)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11723"
            },
            {
                "text": "muscular dystrophy (DOID:9884)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9884"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "serum cystatin c , urine dipstick , urine protein-to-creatinine ratio measured starting amondys 45 ( 2.1 ) 30 milligrams per kilogram body weight weekly ( 2.2 ) administer intravenous ( iv ) infusion 35 60 minutes via in-line 0.2 micron filter ( 2.2 , 2.4 ) dilution required prior ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "amondys 45 injection supplied single dose vials . solution clear slightly opalescent , colorless liquid , may contain trace amounts small , white off-white amorphous particles . \u2022 single-dose vials containing 100 mg/2 ml ( 50 mg/ml ) ndc 60923-227-02",
    "adverseReactions": "amondys 45 contraindicated patients known serious hypersensitivity casimersen inactive ingredients amondys 45. instances hypersensitivity , including angioedema anaphylaxis , occurred patients receiving amondys 45 [ ( 5.1 ) ] .",
    "indications_original": "AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45 [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.",
    "contraindications_original": "Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting AMONDYS 45 ( 2.1 ) 30 milligrams per kilogram of body weight once weekly ( 2.2 ) Administer as an intravenous (IV) infusion over 35 to 60 minutes via an in-line 0.2 micron filter ( 2.2 , 2.4 ) Dilution required prior to administration ( 2.3 )",
    "warningsAndPrecautions_original": "AMONDYS 45 injection is supplied in single dose vials. The solution is a clear to slightly opalescent, colorless liquid, and may contain trace amounts of small, white to off-white amorphous particles.\n\n                        \u2022 Single-dose vials containing 100 mg/2 mL (50 mg/mL)  NDC 60923-227-02",
    "adverseReactions_original": "AMONDYS 45 is contraindicated in patients with known serious hypersensitivity to casimersen or to any of the inactive ingredients in AMONDYS 45. Instances of hypersensitivity, including angioedema and anaphylaxis, have occurred in patients receiving AMONDYS 45 [see Warnings and Precautions (5.1)].",
    "drug": [
        {
            "name": "AMONDYS 45",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14984"
        }
    ]
}